Bellerophon Therapeutics, Inc.
BLPH
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 62.61% | -282.07% | 156.26% | 1.05% | -23.48% |
| Total Depreciation and Amortization | -100.00% | 0.00% | -75.00% | -80.95% | 10.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -189.47% | -49.62% | 63.98% | -25.81% | 0.93% |
| Change in Net Operating Assets | -5,271.08% | -53.63% | -64.13% | 378.77% | -189.95% |
| Cash from Operations | -28.67% | -250.67% | 175.05% | 13.13% | -36.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 148.64% | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -200.00% | -- | -- | -- |
| Cash from Financing | -100.00% | -99.48% | 12,555.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.50% | -159.35% | 287.80% | 12.34% | -36.44% |
